BioMarin director gets 6,140-share stock grant

BIOMARIN PHARMACEUTICAL INC (BMRN) reported that director Robert M. Plenge received a grant of 6,140 shares of common stock in the form of restricted stock units on September 10, 2026, as equity compensation.

Rhea-AI Filing Summary

BIOMARIN PHARMACEUTICAL INC (BMRN) reported that director Robert M. Plenge received a grant of 6,140 shares of common stock in the form of restricted stock units on September 10, 2026, as equity compensation. The grant carries no cash exercise price, and his directly held position after the award is 6,140 shares.

No Rule 10b5-1 trading plan is reported in connection with this grant.

Insider Trade Summary

Grant/Award: 6,140 shares

Grant/Award 1 txn

Insider Plenge Robert M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,140	$0.00	$0.00

Holdings After Transaction: Common Stock — 6,140 shares (Direct)

Footnotes (1)

1. F1. Restricted stock units granted on September 10, 2026. Price not applicable.

Key Figures

Restricted stock units granted: 6,140 units Shares directly held after transaction: 6,140 shares Form 4 non-derivative transactions: 1 transaction

3 metrics

Restricted stock units granted 6,140 units Equity grant to director Robert M. Plenge on September 10, 2026

Shares directly held after transaction 6,140 shares Director Robert M. Plenge’s direct holdings after the September 10, 2026 grant

Form 4 non-derivative transactions 1 transaction Single reported equity award on September 10, 2026

Key Terms

Restricted stock units, Rule 10b5-1 trading plan

2 terms

Restricted stock units financial

"Restricted stock units granted on September 10, 2026. Price not applicable."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported in connection with this grant."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BMRN disclose for Robert M. Plenge?

BioMarin disclosed that director Robert M. Plenge received a grant of 6,140 restricted stock units representing common stock on September 10, 2026, as equity compensation, with no cash price per share applicable to the award.

How many BioMarin (BMRN) shares does Robert M. Plenge hold after this grant?

Following the September 10, 2026 award, Robert M. Plenge is reported as directly holding 6,140 shares of BioMarin common stock, corresponding to the 6,140 restricted stock units granted on that date.

Was the BioMarin (BMRN) grant to Robert M. Plenge made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan applies to the reported grant of 6,140 restricted stock units to director Robert M. Plenge on September 10, 2026.

What type of security was granted to Robert M. Plenge by BioMarin (BMRN)?

Robert M. Plenge received restricted stock units that represent BioMarin common stock. The Form 4 describes them as restricted stock units granted on September 10, 2026, with price per share noted as not applicable.

Did Robert M. Plenge buy or sell any BioMarin (BMRN) shares for cash in this filing?

No. The Form 4 reports only an equity grant of 6,140 restricted stock units to Robert M. Plenge on September 10, 2026, with no cash purchase or sale price associated with the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:55 PM Accepted by SEC EDGAR 09/14/2026 - 06:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plenge Robert M

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		A		6,140	A	$0(1)	6,140	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on September 10, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)